Return to homepagePandemic Pact

AlkaBurst2.0 'Äì A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approach

Grant number: 190110623

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2024

  • Known Financial Commitments (USD)

    $2,475,000

  • Funder

    European Commission

  • Principal Investigator

    Buet Sarah-Meryll

  • Research Location

    France

  • Lead Research Institution

    ALKION BIOINNOVATIONS

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Alkion, a revolutionary biotech company, is developing a breakthrough biorefinery to produce top quality active pharmaceutical ingredients (API) and extracts in plants in a sustainable and cost-effective way. Our core technology combines our disruptive patented automated bioreactor-AlkaBurst2.0 with unique knowhow on gene expression methods, culture media and extraction. Our process offers high productivity and a low carbon footprint. The pharma industry is carbon intensive with recurring problems of quality & safety. Moreover, many critical APIs are outsourced to Asia to cut costs. AlkaBurst2.0 allows a local standardised production of safe & clean APIs in its automated process saving 75% time, 80% space, 95% electricity, 98% water. We first validated the production for Covid-19 natural vaccine adjuvants QS21/7, cannabinoids & certain recombinant proteins for the urgent market demand. We need 'Ǩ7.5M to build & validate our pilot and expect to generate 'Ǩ125M revenue by 2028 with 105 job